|
Título:
|
Therapeutic targeting of HER2–CB2R heteromers inHER2-positive breast cancer
|
|
Autores:
|
Blasco-Benito, Sandra ;
Moreno Gordaliza, Estefanía ;
Seijo-Vila, Marta ;
Tundidor, Isabel ;
Andradas Arias, Clara ;
Caffarel, María M. ;
Caro-Villalobos, Miriam ;
Urigüen, Leyre ;
Diez-Alarcia, Rebeca ;
Moreno-Bueno, Gema ;
Hernández, Lucia ;
Manso Sánchez, Luis Manuel ;
Homar-Ruano, Patricia ;
McCormick, Peter J. ;
Bibic, Lucka ;
Bernadó-Morales, Cristina ;
Arribas, Joaquín ;
Canals, Meritxell ;
Casadó, Vicent ;
Canela, Enric I. ;
Guzmán, Manuel ;
Pérez-Gómez, Eduardo ;
Sánchez, Cristina
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
National Academy of Sciences (USA), 2019-02-26
|
|
Dimensiones:
|
application/pdf
|
|
Nota general:
|
cc_by_nc
info:eu-repo/semantics/openAccess
|
|
Idiomas:
|
|
|
Palabras clave:
|
Estado = Publicado
,
Materia = Ciencias Biomédicas: Medicina: Oncología
,
Materia = Ciencias Biomédicas: Biología: Biología molecular
,
Materia = Ciencias Biomédicas: Biología: Bioquímica
,
Tipo = Artículo
|
|
Resumen:
|
Although human epidermal growth factor receptor 2 (HER2)- targeted therapies have dramatically improved the clinical outcome of HER2-positive breast cancer patients, innate and acquired resistance remains an important clinical challenge. New therapeutic approaches and diagnostic tools for identification, stratification, and treatment of patients at higher risk of resistance and recurrence are therefore warranted. Here, we unveil a mechanism controlling the oncogenic activity of HER2: heteromerization with the cannabinoid receptor CB2R. We show that HER2 physically interacts with CB2R in breast cancer cells, and that the expression of these heteromers correlates with poor patient prognosis. The cannabinoid ?9-tetrahydrocannabinol (THC) disrupts HER2–CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2–HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL. This in turn triggers antitumor responses in vitro and in vivo. Selective targeting of CB2R transmembrane region 5 mimicked THC effects. Together, these findings define HER2–CB2R heteromers as new potential targets for antitumor therapies and biomarkers with prognostic value in HER2-positive breast cancer.
|
|
En línea:
|
https://eprints.ucm.es/56888/1/Blasco-Benito-DBBM-Therapeutic-targeting.pdf
|
